Oncology

Therapeutic antibodies
#Bispecific Antibodies #Interview #Lymphoma #Oncology

Q&A: Targeting difficult to treat lymphomas with a bispecific antibody

DDW Editor Reece Armstrong speaks to Tahi Ahmadi, MD, PhD, Executive Vice President & Chief Medical Officer, Head of Experimental Medicines, Genmab & Jacqueline Nielsen, PhD, Therapeutic Head, Hematology, AbbVie, about the recommendation and the development of epcoritamab. Earlier this year, the European Medicines Agenecy’s (EMA) Committee for Medicinal Products… Read More

#Cancer Research #Exclusive Content

#Cancer drug targets #Cancer therapeutics #Cancer treatment #Oncology

New DDW Highlights podcast: 22 October 2024

The latest episode of the DDW Highlights podcast is now available to listen to below. DDW’s Megan Thomas narrates five key stories of the week to keep DDW subscribers up-to-date on the latest industry updates. As we are halfway through Breast Cancer Awareness Month, our news highlights this week… Read More

#News

FDA
#Astellas Pharma #Biomarkers #FDA #Immuno-oncology #Oncology

FDA approves CLDN18.2-targeted treatment for gastric cancer

The US Food and Drug Administration (FDA) has approved Vyloy (zolbetuximab-clzb) for locally advanced unresectable or metastatic human epidermal growth factor receptor 2 (HER2)-negative gastric or gastroesophageal junction (GEJ) adenocarcinoma. It is approved in combination with fluoropyrimidine- and platinum-containing chemotherapy for the first-line treatment of adults whose tumours are claudin… Read More

#News #Regulatory

#Cancer drug targets #Cancer therapeutics #Cancer treatment #Oncology

This week in drug discovery (14-18 October) 

News round-up for 14-18 October by DDW Senior Digital Content Editor Diana Spencer. As we are halfway through Breast Cancer Awareness Month, our news highlights this week focus on studies that could advance the treatment of cancer in the future, including a new understanding of cancer drug… Read More

#News

Cancer cell
#Cancer drug targets #Drug resistance #EMBL European Bioinformatics Institute #Gene mutation #Genetics / genomics #Oncology #Wellcome Sanger Institute

Drug resistance study boosts discovery of next-generation cancer drugs

New research has detailed each type of cancer mutation that causes drug resistance, helping to uncover targets for drug development and identify potential effective second-line therapies. In a new large-scale study, researchers from the Wellcome Sanger Institute, EMBL’s European Bioinformatics Institute (EMBL-EBI), Open Targets, and collaborators… Read More

#Cancer Research #News #Trending News

Peptide
#Cybrexa Therapeutics #Oncology #Ovarian cancer #Peptide-drug conjugate #Peptides #Phase II trial

Peptide-drug conjugate demonstrates antitumour activity

Cybrexa Therapeutics has dosed the first patient in a Phase II trial of its peptide-drug conjugate (PDC) CBX-12 in ovarian cancer. The primary target patient population for the study is women with platinum-resistant or refractory ovarian cancer who are naïve to TOP1-targeted agents. Read More

#News

Cell therapy
#Cell therapy #Immunotherapy #Oncology #Solid tumours #T cell activation #Turning Science into Business

Are TILs the next big thing in cancer treatment?

DDW’s Megan Thomas speaks with Dr Chantale Bernatchez, Director of Cell Therapy Process Development at CTMC, about tumour infiltrating lymphocyte (TIL) therapy and what's on the horizon for this new class of cell therapy. TIL therapy is a form of cancer immunotherapy. It's an autologous cell therapy, meaning cells are… Read More

#Cancer Research #Exclusive Content

#Business #Cell therapy #Oncology #Solid tumours #Turnstone Biologics

Turnstone Biologics reduces employee headcount by 60%

Turnstone Biologics has announced a “strategic prioritisation of its pipeline”, as well as a workforce reduction of approximately 60% and changes to its leadership team. The cuts are designed to allow the company to focus resources on the continued advancement of its Phase I programme, selected tumour-infiltrating lymphocyte (TIL) therapy… Read More

#Business & Investment #News #Trending News

Breast Cancer Awareness Month
#Breast cancer #Cancer research #Cancer Research UK #Cancer therapeutics #Oncology

How close is a cure for breast cancer?

This Breast Cancer Awareness Month, Diana Spencer takes a look at the current situation and the new therapies on the horizon. Breast cancer is the most common cancer globally, with around 2.3 million new cases every year, according to data from the World Health Organization (WHO). It represents one in… Read More

#Cancer Research #Editor's Choice #Exclusive Content

Radioactive containers
#Akiram Therapeutics #Events #Immunotherapy #Oncology #Radiopharmaceuticals

Radioimmunotherapy drug results to be shared at EANM

Akiram Therapeutics will reveal its research findings on radioimmunotherapy drug candidate AKIR001 at the European Association of Nuclear Medicine (EANM) Congress 2024 in Hamburg, from 19-23 October. 177Lu-AKIR001 holds the potential to become a first-in-class treatment in multiple cancer types, including anaplastic and iodine-refractory thyroid cancer,… Read More

#News

Tumour microenvironment
#FDA #Lymphoma #Oncology #Phase I trial #Recursion #Solid tumours

RBM39 degrader offers “promising approach” in solid tumours

TechBio Recursion will be launching a Phase I/II clinical trial of REC-1245 for the treatment of biomarker-enriched solid tumours and lymphoma, following the go-ahead from the US Food and Drug Administration (FDA). REC-1245 is a potent and selective RBM39 degrader with a potential first-in-class profile. Recursion identified the novel regulatory… Read More

#Cancer Research #News #Regulatory

CAR-T cells attacking a cancer cell
#CAR-T #Cell therapy #High throughput screening #Live cell analysis #Oncology

Characterisation of CAR-T cells: Integrating live-cell analysis and high-throughput cytometry

The development of gene-modified cell therapies, particularly CAR-T cells, has transformed cancer treatment by offering personalised and potentially curative options. This webinar, hosted by DDW and supported by Sartorius, explores the integration of live-cell analysis and high-throughput screening (HTS) by cytometry to enhance the characterisation of CAR-T cells. Key topics… Read More

Webinar date:
Supported by Sartorius
#Webinars

Blood samples in lab
#Drug discovery #Indivumed Therapeutics #Molecular Biology #Oncology #Sample preparation

Fast changes within tumour samples could mislead researchers

Significant changes in the molecular characteristics of tumour samples occur within as little as 10 minutes after surgical removal, a new study led by Indivumed Therapeutics has revealed. The findings underline the importance of rapid snap freezing of tissue samples to reliably capture cancer biology and… Read More

#Cancer Research #News

Cancer immunotherapy
#Immunotherapy #Oncology #The Francis Crick Institute #The Royal Marsden NHS Foundation Trust #UK

UK-wide programme to boost success of immunotherapy

A team of UK universities, hospitals and industry, led by the Francis Crick Institute and The Royal Marsden NHS Foundation Trust, have launched a new platform to understand immunotherapy response and side effects in cancer. The programme will be funded by £9 ($11.7) million from the… Read More

#Cancer Research #News